Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuropsychological testing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    79 result(s) found for: Neuropsychological testing. Displaying page 3 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2006-000654-43 Sponsor Protocol Number: MPC-7869-05-010.04 Start Date*: 2006-07-31
    Sponsor Name:Myriad Pharmaceuticals, Inc
    Full Title: Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in ...
    Medical condition: Mild Dementia of the Alzheimer's Type
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) ES (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000630-30 Sponsor Protocol Number: AC-AD-003 Start Date*: 2015-11-26
    Sponsor Name:AXON NEUROSCIENCE SE
    Full Title: “ADAMANT” A 24-months randomised, placebo-controlled, parallel group, double blinded, multi centre, phase 2 study to assess safety and efficacy of AADvac1 applied to patients with mild Alzheimer’s ...
    Medical condition: Alzheimer’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) SE (Completed) DE (Completed) SK (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2009-010227-62 Sponsor Protocol Number: GE-067-005 Start Date*: 2009-09-09
    Sponsor Name:GE Healthcare Ltd and its Affiliates
    Full Title: A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (F18) Injection for Identifying Subjects with Amnestic Mild Cognitive Impairment who will Convert to Probable Alzhei...
    Medical condition: GE-067-005 will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer for predicting the conversion from amnestic Mild Cognitive Impairment to probable Alzheimer’s disease. Uptake...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10057167 Mental impairment disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-006042-32 Sponsor Protocol Number: GE-067-019 Start Date*: 2012-09-12
    Sponsor Name:GE Healthcare Ltd and its affiliates
    Full Title: A Single-Arm Open-Label Multi-Center Study to Determine the Test-Retest Variability of PET Brain Imaging with Flutemetamol (18F) Injection.
    Medical condition: Subjects with amnestic Mild Cognitive Impairment (aMCI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10057167 Mental impairment disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000342-19 Sponsor Protocol Number: IIT-2017/02 Start Date*: 2018-10-18
    Sponsor Name:Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät
    Full Title: Prospective, randomized, double-blind clinical trial phase II for the anti-inflammatory effects of Curazink (zinc histidine) for 8 weeks in elderly patients with mild cognitive impairment in Alzhei...
    Medical condition: Included are patients with the presence of a moderate or pronounced zinc deficienc and the diagnosis of a mild cognitive disorder, which may be due to an additional investigation (amyloid PET and /...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016663-11 Sponsor Protocol Number: ORA111850 Start Date*: 2010-08-27
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour...
    Medical condition: GSK1521498 is a novel opioid receptor inverse agonist that is being developed for the treatment of obesity.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-023852-10 Sponsor Protocol Number: 18F-AV-45-020 Start Date*: 2011-10-03
    Sponsor Name:Avid Radiopharmaceuticals, Inc.
    Full Title: 18F-AV-45 Amyloid PET Imaging in Primary Progressive Aphasia
    Medical condition: Focal dementia syndromes - primary aphasia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012292 Dementia of the Alzheimer's type NOS LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003747-31 Sponsor Protocol Number: 523001.01.071 Start Date*: 2005-12-27
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Randomised, Double-Blind, Placebo-Controlled, Parallel Group Trial to Confirm the Efficacy, Safety and Tolerability of Ginkgo biloba Special Extract EGb 761® in Patients Suffering from Mild Mental ...
    Medical condition: mild mental impairment
    Disease: Version SOC Term Classification Code Term Level
    10027374
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-004854-25 Sponsor Protocol Number: SPON803-10 Start Date*: 2012-01-10
    Sponsor Name:Cardiff University
    Full Title: TRON: A randomised, double blind, placebo-controlled study of RAD001 (Everolimus) in the treatment of neurocognitive problems in tuberous sclerosis.
    Medical condition: Tuberous Sclerosis Complex (TSC)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10002649 Anorexia nervosa PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2023-000185-34 Sponsor Protocol Number: VAL1221-ITLAFORA-01 Start Date*: 2023-04-19
    Sponsor Name:AZIENDA USL DI BOLOGNA
    Full Title: A SINGLE ARM, OPEN-LABEL, PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF VAL-1221 ON SUBJECTS WITH LAFORA DISEASE
    Medical condition: patients with mid- to late stage Lafora Desease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003763-35 Sponsor Protocol Number: 2016_76 Start Date*: 2018-05-17
    Sponsor Name:centre hospitalier universitaire de Lille
    Full Title: Conservative Iron Chelation by Deferiprone as a disease-modifying Strategy for Amyotrophic Lateral Sclerosis using a Multicentre Parallel group, placebo controlled, Randomized clinical trial
    Medical condition: De novo Amyotrophic Lateral Sclerosis patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004880-33 Sponsor Protocol Number: 18F-FDOPA-BUP-ESC Start Date*: 2023-01-20
    Sponsor Name:Medical University of Vienna, University Department of Psychiatry and Psychotherapy
    Full Title: Reward-specific changes of cerebral dopamine synthesis in healthy volunteers and depressed patients
    Medical condition: Major Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-005112-42 Sponsor Protocol Number: C14-62 Start Date*: 2015-06-22
    Sponsor Name:INSERM
    Full Title: A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003772-39 Sponsor Protocol Number: DEMAND-pilot Start Date*: 2019-12-13
    Sponsor Name:Umeå University
    Full Title: Diet, physical exercise, and metabolic control intervention to reduce the incidence of major neurocognitive disorders among individuals with type 2 diabetes combined with mild neurocognitive impair...
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-005542-38 Sponsor Protocol Number: MK-8931-019 Start Date*: 2014-03-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment...
    Medical condition: prodromal Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DE (Completed) GB (Prematurely Ended) FI (Completed) NL (Prematurely Ended) BE (Completed) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002326-27 Sponsor Protocol Number: COG0201 Start Date*: 2022-09-14
    Sponsor Name:Cognition Therapeutics, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CT1812 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002987-57 Sponsor Protocol Number: AL002-LTE Start Date*: 2023-03-09
    Sponsor Name:Alector Inc.
    Full Title: A Multicenter, Long-Term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer’s Disease
    Medical condition: Early Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004187-30 Sponsor Protocol Number: CO17730 Start Date*: 2011-12-14
    Sponsor Name:Avraham Pharmaceuticals Ltd.
    Full Title: A 36-month, multi-centre, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of low dose Ladostigil in patients with Mild Cognitive Impairment (MCI)
    Medical condition: Patient with Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005031-24 Sponsor Protocol Number: 1289.5 Start Date*: 2014-12-04
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compare...
    Medical condition: Patients with diagnosis of AD according to the following criteria: • Symptoms noticed by the patients and/or informant • Cognitive testing confirming symptoms • Biomarker evidence of AD patholog...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014713 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) PT (Completed) ES (Completed) BE (Completed) AT (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000821-29 Sponsor Protocol Number: SPD503-401 Start Date*: 2020-11-19
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...
    Medical condition: Attention-deficit/hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Trial now transitioned) SE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) PT (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 12 17:30:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA